Journal article

Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus

Zheng Quan Toh, Jennie Kosasih, Fiona M Russell, Suzanne M Garland, Edward K Mulholland, Paul Licciardi

INFECTION AND DRUG RESISTANCE | DOVE MEDICAL PRESS LTD | Published : 2019

Abstract

Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated high vaccine efficacy (>90%) against cervical, vulvar, and vaginal precancers caused by these additional types, and have shown comparable immunogenicity to the shared genotypes to quadrivalent HPV vaccine (4vHPV). Vaccine efficacy and antibody responses for 9vHPV are found to persist for at least five years while longer-term observational studies are ongoing to monitor long-term vaccine effectivene..

View full abstract